Canada’s Drug Agency has released new guidance around aging in place. This guidance is intended to help health systems address Canada’s demographic transition toward an increasingly diverse aging population with an increased need for care and support during the later stages of life.

Today’s the day: we are officially Canada’s Drug Agency.

We are expanding on our existing mandate and functions — which span drugs, medical devices, and clinical interventions — and including developing new programs focused on appropriate use, data and analytics, and system coordination and alignment.

Canada’s Drug Agency has published a national inventory of rare disease registries (RDRs) that includes both registries in Canada and international registries with participants who live in Canada.

Canada’s Drug Agency is pleased to announce the recipients of our 2024 Recognition Awards. These awards honour individuals who are pushing the science of health technology assessment (HTA) forward, mentoring the next generation of leaders, and helping to grow Canada’s reputation for excellence in the field.

A new Environmental Scan from Canada’s Drug Agency examines Canadian data related to alternate level of care (ALC) and the effectiveness of strategies health systems use to reduce ALC times.